• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

典型1型致死性骨发育不全的长期存活情况

Long-term survival in typical thanatophoric dysplasia type 1.

作者信息

Baker K M, Olson D S, Harding C O, Pauli R M

机构信息

Department of Medical Genetics, University of Wisconsin-Madison 53705, USA.

出版信息

Am J Med Genet. 1997 Jun 27;70(4):427-36.

PMID:9182787
Abstract

Thanatophoric dysplasia (TD), a severe skeletal dysplasia, is virtually always lethal neonatally, although a few previous reports have documented survival up to 4.75 years. We present a patient with survival beyond age 9 years and summarize his growth, development and medical history. The common Arg248Cys mutation in the extracellular region of fibroblast growth factor receptor 3 (FGFR3) was identified, eliminating the possibility that his long-term survival is attributable to an atypical mutation. This patient (and at least one other TD long-term survivor) have a rare skin disorder, acanthosis nigricans, which also occurs in Crouzon syndrome when caused by a FGFR3 mutation. Therefore, any molecular model of the origin of acanthosis nigricans secondary to FGFR3 mutations must account for the association of diverse mutations and these cutaneous effects.

摘要

致死性发育异常(TD)是一种严重的骨骼发育不良,几乎总是在新生儿期致死,尽管之前有一些报道记录了存活至4.75岁的病例。我们报告了一名存活超过9岁的患者,并总结了他的生长、发育和病史。在成纤维细胞生长因子受体3(FGFR3)细胞外区域发现了常见的Arg248Cys突变,排除了他长期存活归因于非典型突变的可能性。该患者(以及至少另一名TD长期存活者)患有罕见的皮肤疾病——黑棘皮病,当由FGFR3突变引起时,这种疾病也会出现在克鲁宗综合征中。因此,任何关于FGFR3突变继发黑棘皮病起源的分子模型都必须考虑到不同突变与这些皮肤效应之间的关联。

相似文献

1
Long-term survival in typical thanatophoric dysplasia type 1.典型1型致死性骨发育不全的长期存活情况
Am J Med Genet. 1997 Jun 27;70(4):427-36.
2
A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene.一种伴有发育迟缓及黑棘皮病的新型骨骼发育异常是由成纤维细胞生长因子受体3基因中的Lys650Met突变引起的。
Am J Hum Genet. 1999 Mar;64(3):722-31. doi: 10.1086/302275.
3
Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.
Nat Genet. 1995 Mar;9(3):321-8. doi: 10.1038/ng0395-321.
4
An unusual radiological finding in thanatophoric dysplasia type 1 with common mutation of the fibroblast growth factor receptor-3 (FGFR3) gene (Arg248Cys).
Am J Med Genet. 1997 Jul 11;71(1):122-3.
5
Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3.伴有发育迟缓与黑棘皮症的严重软骨发育不全(SADDAN):由成纤维细胞生长因子受体3的Lys650Met突变导致的一种新型骨骼发育异常的表型分析
Am J Med Genet. 1999 Jul 2;85(1):53-65.
6
Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans.伴有黑棘皮病的克鲁宗综合征中的成纤维细胞生长因子受体3(FGFR3)跨膜突变。
Nat Genet. 1995 Dec;11(4):462-4. doi: 10.1038/ng1295-462.
7
Clinical and biochemical findings of a patient with thanatophoric dysplasia type I: additional finding of dicarboxylic aciduria.一名I型致死性骨发育不全患者的临床和生化检查结果:二羧酸尿症的额外发现。
Cleft Palate Craniofac J. 2002 Mar;39(2):246-8. doi: 10.1597/1545-1569_2002_039_0246_cabfoa_2.0.co_2.
8
Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia.FGFR3基因中R248C错义突变的体细胞和生殖系嵌合现象,导致一种与致死性骨发育不良不同的骨骼发育异常。
Am J Med Genet A. 2003 Jul 15;120A(2):157-68. doi: 10.1002/ajmg.a.20012.
9
Thanatophoric dysplasia type I with syndactyly.I型致死性骨发育不全伴并指(趾)畸形
Am J Med Genet. 1998 Nov 16;80(3):260-2. doi: 10.1002/(sici)1096-8628(19981116)80:3<260::aid-ajmg15>3.0.co;2-s.
10
Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice.携带K644M突变的高度活化的成纤维细胞生长因子受体3(Fgfr3)可使严重侏儒小鼠的生存期延长。
Hum Mol Genet. 2001 Jun 1;10(12):1255-64. doi: 10.1093/hmg/10.12.1255.

引用本文的文献

1
Clinical management and emerging therapies of FGFR3-related skeletal dysplasia in childhood.儿童FGFR3相关骨骼发育不良的临床管理与新兴疗法
Ann Pediatr Endocrinol Metab. 2022 Jun;27(2):90-97. doi: 10.6065/apem.2244114.057. Epub 2022 Jun 30.
2
Should We Stop Calling Thanatophoric Dysplasia a Lethal Condition? A Case Report of a Long-Term Survivor.我们是否应该停止将致死性骨发育不全称为致命病症?一例长期存活者的病例报告。
Palliat Med Rep. 2020 May 14;1(1):32-39. doi: 10.1089/pmr.2020.0016. eCollection 2020.
3
Thanatophoric dysplasia: a case report.
致死性骨发育不良:一例报告。
Pan Afr Med J. 2020 Nov 5;37:220. doi: 10.11604/pamj.2020.37.220.21211. eCollection 2020.
4
Thanatophoric Skeletal Dysplasia: A Case Report.致死性骨发育不良:病例报告。
JNMA J Nepal Med Assoc. 2020 Mar;58(223):185-187. doi: 10.31729/jnma.4488.
5
Morphology and development of a novel murine skeletal dysplasia.一种新型小鼠骨骼发育不良的形态学与发育
PeerJ. 2019 Jul 4;7:e7180. doi: 10.7717/peerj.7180. eCollection 2019.
6
National survey of prevalence and prognosis of thanatophoric dysplasia in Japan.日本致死性骨发育不全患病率及预后的全国性调查。
Pediatr Int. 2019 Aug;61(8):748-753. doi: 10.1111/ped.13927. Epub 2019 Aug 27.
7
Achondroplasia: a comprehensive clinical review.软骨发育不全症:全面的临床综述。
Orphanet J Rare Dis. 2019 Jan 3;14(1):1. doi: 10.1186/s13023-018-0972-6.
8
Growth and development in thanatophoric dysplasia - an update 25 years later.致死性骨发育不良的生长与发育——25年后的最新进展
Clin Case Rep. 2013 Dec;1(2):75-8. doi: 10.1002/ccr3.29. Epub 2013 Nov 15.
9
Thanatophoric dysplasia type I: a rare case report at fetal autopsy.I型致死性骨发育不全:胎儿尸检的一例罕见病例报告。
J Lab Physicians. 2014 Jul;6(2):121-3. doi: 10.4103/0974-2727.141513.
10
Ethical language and decision-making for prenatally diagnosed lethal malformations.产前诊断出致死性畸形的伦理语言与决策
Semin Fetal Neonatal Med. 2014 Oct;19(5):306-11. doi: 10.1016/j.siny.2014.08.007. Epub 2014 Sep 5.